<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> or <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> remain at high residual risk of cardiovascular events even after intensive <z:chebi fb="0" ids="35664">statin</z:chebi> therapy </plain></SENT>
<SENT sid="1" pm="."><plain>While treatment guidelines recommend the addition of a fibrate to <z:chebi fb="0" ids="35664">statin</z:chebi> therapy in this setting, concerns about the potential for <z:hpo ids='HP_0003198'>myopathy</z:hpo> may limit the use of this combination in clinical practice </plain></SENT>
<SENT sid="2" pm="."><plain>These concerns are certainly justified for <z:chebi fb="0" ids="5296">gemfibrozil</z:chebi>, which interferes with <z:chebi fb="0" ids="35664">statin</z:chebi> glucuronidation, leading to elevation in <z:chebi fb="0" ids="35664">statin</z:chebi> plasma concentrations and an increased risk of myotoxicity in combination with a range of commonly prescribed <z:chebi fb="0" ids="35664">statins</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>However, the available evidence refutes suggestions that this is a class effect for fibrates </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="5001">Fenofibrate</z:chebi> does not adversely influence the metabolism or pharmacokinetics of any of the commonly prescribed <z:chebi fb="0" ids="35664">statins</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>This in turn translates to a reduced potential for myotoxicity in combination with a <z:chebi fb="0" ids="35664">statin</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Data are awaited from the ongoing Action to Control Cardiovascular Risk in <z:mp ids='MP_0002055'>Diabetes</z:mp> (ACCORD) study to evaluate the efficacy and safety of <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> plus <z:chebi fb="0" ids="9150">simvastatin</z:chebi> combination therapy in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients </plain></SENT>
</text></document>